MedTrace Logo

Body Composition Analysis and Time to Emergence From Remimazolam

NCT05512559 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2023-01-04

No results posted yet for this study

Summary

Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.

Conditions

  • Remimazolam
  • Body Composition

Interventions

DEVICE

body composition analysis

Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2022-12-30
Completion
2023-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05512559 on ClinicalTrials.gov